{
    "clinical_study": {
        "@rank": "52146", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate buprenorphine and behavioral treatment with and\n      without contingent payment on compliance with pro-social activities.  In addition, we will\n      examine whether blind naltrexone dosing is effective in indicating naltrexone consumption."
        }, 
        "brief_title": "Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13", 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Please contact site for information."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000231", 
            "org_study_id": "NIDA-06969-13", 
            "secondary_id": "R01-06969-13"
        }, 
        "intervention": {
            "intervention_name": "Buprenorphine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Buprenorphine"
        }, 
        "lastchanged_date": "August 16, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Burlington", 
                    "country": "United States", 
                    "state": "Vermont", 
                    "zip": "05401"
                }, 
                "name": "Treatment Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Buprenorphine Detoxification With Two Types of Treatment. BBD IV", 
        "overall_official": {
            "affiliation": "University of Vermont", 
            "last_name": "Warren Bickel, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "Drug use"
            }, 
            {
                "measure": "Retention"
            }, 
            {
                "measure": "Weeks abstinent"
            }, 
            {
                "measure": "Weeks continuous abstinence"
            }, 
            {
                "measure": "Overall treatment outcome"
            }, 
            {
                "measure": "Naltrexone consumption"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000231"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Vermont", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1992", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1994"
    }, 
    "geocoordinates": {
        "Treatment Research Center": "44.476 -73.212"
    }
}